tiprankstipranks
Trending News
More News >
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
US Market
Advertisement

Amicus (FOLD) Earnings Dates, Call Summary & Reports

Compare
1,033 Followers

Earnings Data

Report Date
Nov 05, 2025
TBA (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
0.04
Last Year’s EPS
-0.02
Same Quarter Last Year
Based on 8 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Jul 31, 2025|
% Change Since: 18.86%|
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook for Amicus Therapeutics, driven by strong revenue growth and strategic advancements despite increased operating expenses and a reported net loss.
Company Guidance -
Q3 2025
During the Amicus Therapeutics Second Quarter 2025 Financial Results Conference Call, the company provided a robust set of metrics reflecting their positive financial performance and strategic guidance. They reported a 22% year-over-year increase in total revenue, reaching $154.7 million, with the U.S. contributing 42% of this revenue. The company achieved their 17th consecutive quarter of double-digit sales growth at constant exchange rates (CER), with Galafold showing a 13% year-over-year increase in patient growth and contributing $128.9 million in revenue, marking a 12% growth at CER. Pombiliti and Opfolda generated $25.8 million in revenue, a 58% increase at CER, with significant commercial momentum in the U.S. and Europe. Amicus reiterated their confidence in achieving combined sales of $1 billion from Pombiliti and Opfolda by the end of 2028 and aims to achieve GAAP profitability in the second half of 2025. The company also highlighted their strategic partnership with Dimerix, advancing DMX-200, a first-in-class compound in Phase III development for FSGS, with full enrollment of the ACTION3 study expected by the end of the year.
Consistent Double-Digit Revenue Growth
Amicus Therapeutics achieved its 17th consecutive quarter with double-digit sales growth in its core business, including a 22% increase in total revenue over the same period in 2024.
Galafold Patient Growth
Galafold delivered 13% year-over-year patient growth this quarter and is on track to achieve the highest number of global patient starts this year.
Strong Sales for Pombiliti and Opfolda
The second quarter marked the strongest commercial demand for Pombiliti and Opfolda since their launch, with revenue reaching $25.8 million, up 58% at constant exchange rates.
Strategic Partnerships and Pipeline Expansion
Amicus advanced its partnership with Dimerix for DMX-200, a first-in-class compound for a rare kidney disease, with the pivotal Phase III ACTION trial progressing well.
Positive Financial Outlook
The company is on track to achieve GAAP profitability in the second half of the year, with full-year 2025 financial guidance reaffirmed, including total revenue growth of 15% to 22%.

Amicus (FOLD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

FOLD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 05, 2025
2025 (Q3)
0.04 / -
-0.02
Jul 31, 2025
2025 (Q2)
-0.12 / -0.08
-0.05-60.00% (-0.03)
May 01, 2025
2025 (Q1)
-0.05 / -0.07
-0.1656.25% (+0.09)
Feb 19, 2025
2024 (Q4)
0.01 / 0.05
-0.11145.45% (+0.16)
Nov 06, 2024
2024 (Q3)
<0.01 / -0.02
-0.0771.43% (+0.05)
Aug 08, 2024
2024 (Q2)
-0.06 / -0.05
-0.1566.67% (+0.10)
May 09, 2024
2024 (Q1)
-0.06 / -0.16
-0.1811.11% (+0.02)
Feb 28, 2024
2023 (Q4)
-0.06 / -0.11
-0.1942.11% (+0.08)
Nov 08, 2023
2023 (Q3)
-0.08 / -0.07
-0.1241.67% (+0.05)
Aug 08, 2023
2023 (Q2)
-0.11 / -0.15
-0.2128.57% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

FOLD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 31, 2025
$6.13$5.99-2.28%
May 01, 2025
$7.68$6.68-13.02%
Feb 19, 2025
$9.85$9.56-2.94%
Nov 06, 2024
$11.74$11.24-4.26%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Amicus Therapeutics (FOLD) report earnings?
Amicus Therapeutics (FOLD) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).
    What is Amicus Therapeutics (FOLD) earnings time?
    Amicus Therapeutics (FOLD) earnings time is at Nov 05, 2025, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is FOLD EPS forecast?
          FOLD EPS forecast for the fiscal quarter 2025 (Q3) is 0.04.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis